Phaseline

Companies › KeyBioscience

KeyBioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KBP-336
Dual Amylin and Calcitonin Receptor agonist
CALCR, ABCAMPhase 2Osteoarthritis in the KneeNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06833749KBP-336Phase 2Osteoarthritis in the KneeImmunologyNov 2026

Targets

CALCR (1) ABCAM (1)

Companies with the same targets

Novo Nordisk AbbVie Eli Lilly

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.